ACE-031: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

ACE-031 (Ramatercept, CAS 1169766-01-1) is a recombinant fusion protein formed by the extracellular domain of the activin receptor type IIB (ActRIIB) joined to the Fc fragment of a human IgG1. It acts as a soluble decoy receptor that sequesters myostatin (GDF-8) and other ligands of the TGF-β family, blocking the signaling that limits skeletal muscle growth. Research reagent intended exclusively for research use.

ACE-031, also identified as Ramatercept and ActRIIB-Fc, is a recombinant fusion protein designed as a "ligand trap" within the transforming growth factor beta (TGF-β) signaling pathway. It was developed by Acceleron Pharma as a soluble molecule that reproduces the extracellular domain of the activin type IIB receptor (ActRIIB), covalently fused to the constant fragment (Fc) of a human immunoglobulin G1. This architecture places it in the class of Fc fusion proteins, not in that of short peptides: it is a dimeric macromolecule of considerable size in which the Fc component prolongs the circulating half-life and facilitates production and purification, while the ActRIIB domain retains the ability to recognize and bind its natural ligands. Because of its recombinant biologic nature, there is no molecular formula or single, well-defined molecular weight available in the sense in which they are reported for small molecules; the assigned CAS (1169766-01-1) identifies the entity as such.

The mechanistic basis of ACE-031 revolves around the negative regulation of muscle mass physiologically exerted by myostatin (GDF-8), a member of the TGF-β superfamily that acts as an endogenous brake on skeletal muscle growth. Under normal conditions, myostatin and related ligands such as activin A and GDF-11 bind to membrane ActRIIB receptors, recruit type I receptors, and trigger the phosphorylation of the SMAD 2/3 proteins, which translocate to the nucleus and repress hypertrophy and satellite-cell differentiation programs. By introducing an excess soluble ActRIIB domain, ACE-031 functions as a decoy: it captures these circulating ligands before they reach the membrane receptors, reducing SMAD2/3 signaling and releasing the muscle from that tonic inhibition. The result observed in preclinical models is an increase in muscle mass and strength. It is important to emphasize that ACE-031, by targeting the receptor and not exclusively myostatin, also sequesters other ligands of the family (activins, GDF-11, and related BMPs), which broadens its spectrum of action but also explains part of its off-target effect profile.

In the field of documented research, ACE-031 was studied mainly in the context of disorders with loss of muscle mass. The development programs explored its use in models of Duchenne muscular dystrophy and evaluated its effect on muscle volume in early-phase studies in human subjects, including work in healthy postmenopausal women as a pharmacological characterization group. These studies described measurable increases in muscle volume and changes in biomarkers related to muscle and bone metabolism, consistent with inhibition of the ActRIIB pathway. However, the clinical development of ACE-031 was interrupted: in the trials, safety signals of a vascular and mucocutaneous type were observed—among them epistaxis (nosebleeds), telangiectasias, and gingival bleeding—attributed to the modulation of TGF-β ligands involved in vascular homeostasis. For this reason, the molecule did not advance toward regulatory approval and today is handled as a research tool, not as an available drug. This history is a central fact for any experimental design: it illustrates both the potency of myostatin inhibition on muscle and the risks of a broad inhibition of the pathway.

From the standpoint of research applications, ACE-031 is of interest as a pharmacological probe for interrogating myostatin biology and ActRIIB/SMAD signaling in models of atrophy, experimental sarcopenia, cachexia, and muscular dystrophies. It allows in vitro and in vivo study of how suppression of the inhibitory signal affects myofiber hypertrophy, satellite cell activation, metabolic remodeling of muscle, and muscle-bone interactions, since the pathway also participates in the regulation of bone mass. Its comparison with more selective myostatin inhibitors (anti-myostatin antibodies, other ligand traps, and ActRIIB variants engineered for greater selectivity) is a recurring topic in the pathway's literature, precisely because the broader binding profile of ActRIIB-Fc relative to targeted approaches helps dissect which effects depend specifically on GDF-8 and which on activins or GDF-11.

With regard to the level of evidence, ACE-031 occupies an intermediate position: it has early-phase human research data in addition to a consistent body of preclinical work, which distinguishes it from compounds with evidence only in animal or in vitro models. Nevertheless, the fact that its development was halted for safety reasons means that there is no clinical validation of long-term efficacy and safety and that it is not an approved entity for any therapeutic use. Any interpretation of its effects must be made within that honest framework: it is an experimental biologic whose current value lies in the study of the myostatin/ActRIIB pathway in laboratory contexts. As a research reagent, its handling requires the usual conditions for recombinant fusion proteins —cold storage, careful reconstitution, and protection against freeze-thaw cycles— to preserve the structural integrity of the binding domain and the Fc fragment.